Reuters logo
1 年前
BRIEF-Immunomedics says sacituzumab govitecan demonstrates efficacy, safety in patients
2016年6月6日 / 晚上7点27分 / 1 年前

BRIEF-Immunomedics says sacituzumab govitecan demonstrates efficacy, safety in patients

June 6 (Reuters) - Immunomedics Inc :

* Sacituzumab govitecan (IMMU-132) demonstrates efficacy and safety in non-small-cell lung cancer patients with multiple prior treatments, including immuno-oncology Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below